Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Thrombosis Research|January 15, 1992
Reduced guanine nucleotide-stimulated polyphosphoinositide specific phospholipase C in platelet hyperaggregation in IDDME J Bastyr, A I Vinik
The American Journal of Medicine|June 1, 1990
Platelet activity and phosphoinositide turnover increase with advancing ageE J Bastyr, M M Kadrofske, A I Vinik
Diabetes|September 1, 1989
Decreased platelet phosphoinositide turnover and enhanced platelet activation in IDDME J Bastyr, M M Kadrofske, R C Dershimer, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|April 7, 1999
Safety of insulin lispro: pooled data from clinical trialsN B Glazer, S Zalani, J H Anderson, et al.
Oncogene|February 1, 1993
Low molecular weight GTP-binding proteins are altered in platelet hyperaggregation in IDDME J Bastyr, J Lu, R Stowe, et al.
Diabetes Care|January 1, 1990
Corrected Q-T interval prolongation as diagnostic tool for assessment of cardiac autonomic neuropathy in diabetes mellitusJ M Gonin, M M Kadrofske, S Schmaltz, et al.
Clinical Therapeutics|November 24, 1999
Insulin lispro in the treatment of patients with type 2 diabetes mellitus after oral agent failureE J Bastyr, M E Johnson, M E Trautmann, et al.
Diabetes, Obesity & Metabolism|February 28, 2001
Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lisproE J Bastyr, Y Huang, R L Brunelle, et al.
Diabetes, Obesity & Metabolism|January 22, 2011
The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO studyG E Umpierrez, T Blevins, J Rosenstock, et al.
Diabetes Care|September 10, 1999
Metabolic and immunologic effects of insulin lispro in gestational diabetesL Jovanovic, S Ilic, D J Pettitt, et al.
Pageof 2